A review of 40 years of enteric antimicrobial resistance research in Eastern Africa: what can be done better? by unknown
Omulo et al. Antimicrobial Resistance and Infection Control  (2015) 4:1 
DOI 10.1186/s13756-014-0041-4REVIEW Open AccessA review of 40 years of enteric antimicrobial
resistance research in Eastern Africa: what can
be done better?
Sylvia Omulo1, Samuel M Thumbi1, M Kariuki Njenga2 and Douglas R Call1*Abstract
The emergence and persistence of antimicrobial resistance is driven by varied factors including the indiscriminate
use of antibiotics and variable drug efficacy and presents a major threat to the control of infectious diseases.
Despite the high burden of disease in sub-Saharan Africa and the potential health and economic consequences, the
level of research on antimicrobial resistance in the region remains unknown. Little data exists to quantify the contribution
of different factors to the current levels of antimicrobial resistance. To identify the factors that contribute most to the
emergence, amplification, persistence and dissemination of antimicrobial resistance in humans and animals, we used the
PRISMA 2009 guidelines to conduct a systematic review of studies on antibiotic-resistant enteric bacteria in Eastern Africa.
We searched PubMed and Google Scholar databases and identified 2,155 probable articles, of which 89 studies on
humans and 28 on animals remained after full-text review. These were articles from Kenya, Tanzania, Uganda, Ethiopia,
Rwanda and Burundi, published between 1974 and 2013, that reported resistance in Salmonella, Shigella, Escherichia coli
and Vibrio sp. The majority (98%) of human studies were based on hospital- (rather than community-wide) sampling and
although they report high levels of antimicrobial resistance in the region, study design and methodological differences
preclude conclusions about the magnitude and trends of antimicrobial resistance. To remedy this, we discuss and
propose minimum reporting guidelines for the level of detail that should be explicitly provided for antimicrobial resistance
study designs, testing of samples and reporting of results that would permit comparative inferences and enable meta-
analyses. Further, we advocate for increased focus on community- rather than hospital-based sampling to provide a better
indication of population-wide trends in antimicrobial resistance. This approach, together with the establishment of a
robust regional surveillance network, should over time build a pool of evidence-based data useful for policy decisions and
interventions aimed at controlling antimicrobial resistance.
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Since the discovery of penicillin in 1928, antibiotics and
other antimicrobial therapies have been used to control
both old and new emerging pathogens, resulting in glo-
bal improvements in disease outcomes and increments
in life expectancy [1,2]. However, the rapid emergence of
antimicrobial resistance (AMR) by microbial pathogens
threatens to reverse the public health gains made since
widespread use of antibiotics was adopted. AMR is not a
recent phenomenon, [2] and with decreasing options* Correspondence: drcall@vetmed.wsu.edu
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unless otherwise stated.for- and production of newer antibiotics [3-6] the con-
trol of diseases has become a challenge, particularly in
low- and middle-income countries where infectious dis-
eases, poverty and malnutrition are endemic.
The emergence of AMR is a complex process often in-
volving the interplay of human, environmental and
pathogen-related factors [1,2,7,8]. In sub-Saharan Africa,
the endemicity of acute respiratory infections, diarrheal
diseases, HIV/AIDs, tuberculosis, malaria and helminthic
infections has increased the demand for antimicrobial ther-
apies both for prophylaxis and treatment. Further, short-
falls in the healthcare environment ranging from limited
diagnostic capacity and resources, unregulated access to
antibiotics, constrained access to health facilities and poorThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Key search terms used in PubMed and Google
scholar
Initial search terms Refining terms
“Antibiotic resistan*” “east* Africa*”
“Antimicrobial* resistan*” “east* Africa*countr*”
“Drug* resistan*” “Kenya*”
“Multi-drug resistan*” “Uganda*”
“Multidrug resistan*” “Tanzania*”
“Multiple-drug resistan*” “Ethiopia*”
“Multiple drug* resistan*” “Rwanda*”
“Antibiotic* susceptib*” “Burundi”
“Antimicrobial* susceptib*” “enterobacteria*”
“Drug* susceptib*” “enter* pathogen*”
“Multi-drug susceptib*” “diarrh* pathogen*”
“Multidrug susceptib*” “Salmonella* resistan*”
“Multiple-drug susceptib*” “Shigella* resistan*”
“Multiple drug* susceptib*” “Vibrio resistan*”
“Escherichia* resistance*”
Initial search terms included words used to filter out publications that did not
address antimicrobial resistance. Refining terms were then applied to select only
articles from the study region and on the pathogens of interest. Truncation marks
(*) indicate that different extensions of the main stem of words were used.
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ingly stoked the demand for antibiotics. Veterinary use of
antibiotics is also thought to contribute to antibiotic resist-
ance in humans although little is known about how signifi-
cant this contribution is in sub-Sahara Africa. Our ability
to assess these contributions is limited largely by the ab-
sence of surveillance on antibiotic use both for therapeutics
and prophylaxis. Unfortunately, only limited resources
have been devoted to researching of this problem [10].
In 2011, the Global Antimicrobial Resistance Partner-
ship (GARP) - Kenya Working Group stated: “without
knowing the levels or trends of antibiotic resistance or
how key actors are performing, it is impossible to make
rational recommendations or monitor the effectiveness
of interventions”. We therefore conducted a review of
published work from countries in eastern Africa (Kenya,
Uganda, Tanzania, Rwanda, Burundi and Ethiopia) to as-
sess what can be learnt from published data on AMR in
the region. We focused on antibiotic-resistant enteric bac-
teria because these represent the most immediate urgent
global concern [5,6] and diarrheal diseases are among the
most common causes of morbidity and mortality in low-
income nations, disproportionately affecting children
under the age of five [8,13]. Our goal was to critically
analyze the progress of human and animal research in the
region and discuss principles that are potentially useful to
guide efforts aimed not only at controlling AMR in bac-
teria, but also in viruses, protozoa and fungi.
Methods
Between October 2013 and March 2014, PubMed and
Google Scholar databases were queried for articles con-
taining the search terms presented in Table 1. A propor-
tion of research articles from eastern Africa were
published in journals that are not indexed in MEDLINE.
Consequently, reference lists from identified articles were
used to collate additional publications. Articles were se-
lected for further evaluation based on the following inclu-
sion criteria: (i) relevance to antimicrobial resistance in
enteric bacteria, (ii) publication in English or French, and
(iii) accessibility of the full-length article. For our purpose,
selection was not limited by the year of publication; histor-
ical data was useful in informing us on the progress of
AMR research in the study area.
We reviewed the abstracts of all articles that met the
above inclusion criteria. Where insufficient detail was pro-
vided, the entire article was reviewed before its inclusion
or exclusion was determined. Duplicate references or pub-
lications reporting the same data in different journals were
excluded. Most articles (82%) on antibiotic-resistant E. coli
from humans were identified by scanning reference lists of
selected publications. Other relevant articles were obtained
through personal references and publications posted in
curriculum vitae of some of the authors.Additional general information was garnered from re-
ports by the Alliance for the Prudent Use of Antibiotics
[9,13], the Ecumenical Pharmaceutical Network [11], the
World Health Organization [3-6] and the Global Anti-
biotic Resistance Partnership [10]. Remnant literature
resulting from the search described above provided use-
ful information on AMR in the greater African region.
Data extraction for analysis
The fields considered for this review included author,
year of publication, study duration, country, study set-
ting (rural, urban), study design (hospital-, laboratory- or
community-based), age demographics (children, adults)
or studied animal, sample type collected, laboratory tests
performed, laboratory standards used for interpretation
of results, bacterium (genus) isolated, number of isolates
obtained, number of resistant isolates and antibiotics
tested. For analysis: (i) study “settings” were classified as
‘mixed’ for samples drawn from both rural and urban
populations; peri-urban and urban studies were pooled;
(ii) study “designs” were considered ‘hospital-based’ if
exclusively conducted in a hospital laboratory as part of pa-
tient management or if they contained AMR data extracted
from hospital/patient records; ‘laboratory-based’ if they
retrospectively analysed stored samples or clinical samples
that were not used for patient management; or ‘commu-
nity-based’ if based on population-scale sampling irre-
spective of disease status; (iii) bacteria were collectively
identified by their genus (except E. coli); and (iv)
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using one name (thus cotrimoxazole included sulfa-
methoxazole/trimethoprim while augmentin included
amoxicillin-clavulanic acid) or when authors used gen-
eral classifications (as in the case of sulphonamides,
which therefore included sulfisoxazole, sulphadiazine,
sulfamethoxazole).
Given variation in study execution and reporting tech-
niques, publications were carefully scrutinized when
extracting data. Occasionally, this involved making the
best possible judgments from the available data. When
crucial information was required but lacking, authors
were contacted (at least three times) via email to provide
clarification. Eventually, such publications were either
included or excluded depending on whether or not the
required information was provided. Data extracted from
included articles was summarized in Excel and Sigma-
Plot v11 · 5.
Results
Study selection
Our search terms (Table 1) identified 2,155 probable ar-
ticles. Of these, only 105 English and 12 French articles
published between 1974 and 2013 met the criteria for
inclusion (Figure 1). 89 were studies on humans and 28
on animals. One study [14] concurrently tested humanFigure 1 Flow diagram summarizing the selection of publications for
(underlined) and reasons for exclusion are shown. CV: Curriculum vitae.and animal samples and was thus counted both as a hu-
man and animal study. Generally, the number of publi-
cations increased progressively from 1974 to 2013
(Figure 2).
Study characteristics
Population
Of the 89 articles focused on research in humans, 66%
were from Kenya and Ethiopia with those from Burundi,
Rwanda, Tanzania and Uganda accounting for the
remaining 34% (Table 2). Most of these were hospital-
based (61%) or lab-based (37%) studies reporting cross-
sectional, retrospective or outbreak-related AMR data.
Only two studies were considered community-based. Iso-
lates were more commonly cultured from persons of all
ages (66%) than solely from adults (14%) or children (20%)
and represented a fair distribution of both rural (30%) and
urban (49%) settings; mixed settings accounted for the
remaining 21%. Similar to human studies, animal studies
were mainly from Kenya and Ethiopia. No animal studies
were identified from Uganda, Rwanda and Burundi and
only one study was identified from Tanzania (Table 2).
These studies were predominantly community-based
(93%) with samples drawn from cattle, chickens, pigs,
camels, sheep, goats, rats and fish mostly in urban (75%)
than rural (24%) or mixed settings (1%). Studies thatreview. Two exclusion steps were applied. Total articles excluded
Figure 2 Distribution of reviewed publications from 1974 to 2013. Trend (based on year of publication) shown for human (blue full dots)
and animal (red circles) studies from the six countries studied. Regression lines show an increasing trend in the number of publications from the
mid-1970s to date.
Table 2 Distribution of publications from the six countries studied shown by age of study subjects and by
pathogen tested
Bur Eth Ken Rwa Tan Uga
A. Human studies Total Citation
E. coli Adults - - 1 - - - 1 [15]
Children - - 5 - - 1 6 [14,16-20]
All ages - 1 2 - - 1 4 [21-24]
(n) 0 2 8 0 0 2 11
Salmonella sp. Adults - 4 5 - - - 9 [25-33]
Children - 2 5 - 1 1 9 [34-42]
All ages - 4 10 1 1 16 [43-58]
(n) 0 10 20 1 1 2 34
Shigella sp. Adults - 2 - - - - 2 [59,60]
Children - 2 - - 1 - 3 [61-63]
All ages 4 9 6 8 1 1 29 [64-91]
(n) 4 13 6 8 2 1 34
Vibrio sp. All ages 1 1 - 4 3 1 10 [92-101]
N 5 25 34 13 6 6 89
B. Animal studies
E. coli - 1 11 - - - 12 [14,102-112]
Salmonella sp. - 14 1 - 1 - 16 [113-128]
N 0 15 12 0 1 0 28
(n) is the total number of studies on a particular pathogen from each country; N is the cumulative number of human and animal studies from each country.
Last column shows citations.
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milk, meat and eggs were included in the analysis. Ap-
proximately half (53%) of animal studies focused on
poultry or cattle.
Laboratory methods
For all studies, testing against resistance to antibiotics was
done through agar dilution, broth microdilution, tube di-
lution, disk diffusion, E-test, Sensititre- (automated) or
VITEK-2 (semi-automated) tests. Disk diffusion was by far
the most commonly used method, particularly in human
studies (90% vs. 66% in animal studies). Regardless of the
method employed, only 40% of human studies compared
with 78% of animal studies reported using some form of
standard interpretation guidelines. These included guide-
lines by the Clinical and Laboratory Standards Institute,
[formerly the National Committee for Clinical Laboratory
Standards (NCCLS)], British Society for Antimicrobial
Chemotherapy, Comité de I'Antibiogramme de la Société
Française de Microbiologie, Deutsches Institut für
Normung (DIN) 58940, the Danish Integrated Anti-
microbial resistance Monitoring and Research Program
and the World Health Organization (WHO). Neverthe-
less, CLSI guidelines were the most commonly used
(70% of human studies from Kenya and 67% of animal
studies from Ethiopia). The use of reference strains for
quality assurance was reported in 62% of human- and
56% of animal studies. E. coli ATCC 25922 was the
most commonly identified standard isolate (human:
81% and animal: 87%).
Pathogens and resistances tested
Considering only one pathogen per study, Salmonella
(38%) and Shigella (38%) were most commonly studied
pathogens in humans, followed by E. coli (13%) and Vib-
rio sp. (11%) consecutively (Table 2). These proportions
remained unchanged when 14 studies that concurrently
tested two pathogens, four that tested three pathogens and
two that evaluated all four pathogens were accounted for.
In all, susceptibility results for these pathogens were re-
ported for over 30 different antibiotics. However, for spe-
cific bacteria, E. coli, Salmonella and Shigella sp. isolates
were most commonly (≥50% of studies) tested for resist-
ance to ampicillin (Amp), chloramphenicol (Chl), cipro-
floxacin (Cip), cotrimoxazole (Cot), gentamycin (Gen) and
tetracycline (Tet) while Vibrio sp. for resistance to Amp,
Chl and Tet. Animal studies on the other hand isolated ei-
ther Salmonella (59%) or E. coli (41%), testing these mainly
for resistance to Amp, Chl, Cot, Gen, kanamycin (Kan),
Tet, nalidixic acid (Nal), streptomycin (Str), sulphonamides
(Sul) and trimethoprim (Tri) [see Additional file 1]. For
our purposes, comparisons between reported resistance
levels were not performed given the large variability in re-
ported variables and reporting styles.In general, AMR in the region was reported to be in-
creasing, presumably driven by multiple factors (Table 3).
Importantly, while most authors made claims about the
mechanisms that were likely to contribute to the ob-
served AMR patterns, no studies were identified that ac-
tually investigated or quantified the contributory roles of
any of these factors within the region.
Discussion
The goal of this review was to assess the current know-
ledge of AMR for enteric bacteria found in eastern
Africa. Specifically, we set out to understand the contribu-
tion of different factors to the emergence, amplification,
persistence and dissemination of antibiotic resistance for
both human and animal populations. After collating the
data and conducting exploratory analyses, we found it dif-
ficult to make meaningful comparisons from studies due
to the differences in study designs and styles of reporting
of results. Here we provide a general view of the progress
made in AMR research while highlighting gaps that im-
pede our understanding of the dynamics of AMR in east-
ern Africa. We also propose potential ways to address
these gaps to improve the quality of AMR data and build a
pool of evidence-based data for this region. These are
likely to improve our understanding of the mechanisms
that contribute most to AMR, the regional prevalence and
the trends of AMR in the short- or long-term.
Trend of AMR research in eastern Africa
The gradual increase in publications from the mid-70s
to date suggests that AMR research is gaining increasing
attention within eastern Africa (Figure 2). While most of
the reported AMR research was conducted in Kenya and
Ethiopia, we also observed an increase in AMR research
in Uganda and Tanzania, although fewer publications
were identified from these countries (Table 2). It is pos-
sible that researchers from these countries have focused
their AMR research on non-enteric pathogens such as
Mycobacterium tuberculosis, which were not considered
in this review. We found very limited data from Rwanda
and Burundi after 1995, perhaps owing to historical
political events that could have disrupted health-related
surveillance or research studies if these existed. We, however,
attempted to gather such data by including reported studies
carried out on these citizens in refugee camps of neighboring
countries [96].
Notably, even in countries from which more publica-
tions were derived, research progress on AMR in enteric
bacteria appears slow relative to the global awareness of
AMR, supporting the seemingly low prioritization of this
problem in sub-Saharan Africa [10]. This is worrisome
considering that a sizable portion of health budgets
in these countries are allocated to the acquisition of an-
tibiotics for the prevention or treatment of infectious
Table 3 Factors that explain the prevailing state of AMR in eastern Africa
I. Factors that favor the emergence, dissemination
and/or persistence of AMR
a) Factors common to human and animal studies
• Ease of access (cheap, widely available) to antibiotics Kenya [19,32,36,51,123]; Uganda [22];
Ethiopia [30]; Tanzania [39,85]
• Antibiotic use practices, including self-medication, high frequency of
antibiotic use, sub-therapeutic use or indiscriminate use
Kenya [19,26,31,32,36,51,54,77,108,129];
Ethiopia [27,47,88,89,120,125]; Tanzania [85,113]
b) Human studies
• Over-prescription at health facilities due to limited diagnostics resources Ethiopia [89]; Kenya [38]
• Severe infections requiring different antibiotics Rwanda [79]
• Human importation of antibiotic resistant bacteria Burundi [75]
• Nosocomial or community transmission of resistant bacteria Kenya [14,36,78]; Rwanda [44]
c) Animal studies
• Resistant bacteria imported via contaminated food Kenya [26]; Ethiopia [122,125,126]
• Antibiotic use in humans Kenya [105-107]; Ethiopia [122,125]
• Animal-animal contact Ethiopia [119]
• Animal-human close co-existence increasing contact Kenya [103]
• High antibiotic use in animals in small production systems,
poor farm management practices disseminating resistant bacteria
Kenya [107]; Ethiopia [126]
• Housing contamination Ethiopia [124]
• Contamination during handling animal products. Kenya [107]; Ethiopia [115,117,125]
II. Factors that contribute to the reduction of AMR
• High cost of antibiotic Kenya [36]; Ethiopia [117,118]Ɨ
• Limiting antibiotic availability Uganda [22]; Rwanda [79]; Ethiopia [118,119]Ɨ
• Periodic withdrawal of antibiotics from public use Kenya [37]; Rwanda [79]
• Parenteral administration of antibiotics Ethiopia [47]
• Infrequent or prudent use of antibiotics Kenya [104,107,123]Ɨ; Ethiopia [115,117,120,125,127]Ɨ
List of risk factors that are thought to contribute to the state of antimicrobial resistance in Eastern Africa as suggested both by studies on AMR in humans and
animals. Country and relevant citation shown in the column on the right. ƗAnimal studies.
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fewer publications on animal studies over time indicate
a biased focus on AMR research in humans. Justifiably,
human diseases are a primary concern, particularly when
those affected are the most economically productive
sub-populations. Nevertheless, in the case of zoonotic
food and water-borne diseases, control of human disease
relies, in part, on the control of animal diseases. With
projected increases in human and food animal popula-
tions in the coming decades, increased interactions be-
tween humans and animals are inevitable, particularly
where land for expanding populations is scarce. Presum-
ably, animals can also serve as reservoirs of antibiotic re-
sistant enteric bacteria, underscoring the importance of
integrating animal and human research to maximize
benefits for both sectors (i.e., a One Health focus).
Based on our review, research in eastern Africa has
been focused on AMR prevalence and patterns; a trend
that has persisted since the 1970s. The frequency of
studied bacteria (Salmonella, Shigella in humans andSalmonella and E. coli) corresponds with the frequency
of their implication in diarrheal diseases in the region,
their potential for zoonotic transmission to humans and
their high rates of resistance to available treatment regi-
mens (Amp, Chl, Cip, Cot, Gen, Kan and Tet). Probable
drivers and potential mitigation actions were universally
discussed by study authors. Nevertheless, no study dir-
ectly tested these ideas or assessed the effectiveness of
AMR interventions. Similarly, none of the studies tested
associations between these putative risk factors and re-
ported prevalence of AMR; consequently, although mech-
anistic explanations were suggested and may be intuitively
reasonable, they remain speculative. While the potential
role of risk factors such as antibiotic use is undisputed, a
consistent focus on cross-sectional prevalence data does
not build our understanding of the proportional contribu-
tions and distributions of each of these factors in different
environments and subpopulations. Thus, while useful for
qualitative purposes, unstructured and uncoordinated
prevalence data is insufficient for estimating changes over
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that the following issues present the greatest challenges to
drawing inferences from the existing research:
Study execution
Study and sampling design Of the three study designs
(hospital-, laboratory- and community-based), AMR
studies involving humans were predominantly hospital-
or laboratory-based. Samples and isolates for these
studies were obtained primarily from patients seeking
treatment at health facilities and, in general, reported
high prevalence of AMR. While hospital sampling is
more convenient and less expensive than field-level ran-
dom sampling, it likely represents populations that -
owing to failures in self-medication with variable-quality
antibiotics - are pre-selected for resistant strains of bac-
teria thereby inflating reports of AMR prevalence. Simi-
larly, where the hospital environment facilitates infection
transmission, as in the case of non-typhoidal Salmonella
(NTS), [26,130] hospital and community prevalence may
differ, particularly in communities that rely on non-
antibiotic forms of therapy [23]. Studies that have
reported the occurrence of AMR in populations not
previously exposed to antibiotics [131-136] or reported
unchanged AMR prevalence despite frequent- [137-139]
or infrequent-[140] antibiotic exposure, indicate that the
prevalence of- and drivers for AMR may vary. Conse-
quently, while hospital samples provide an important
means of characterizing AMR, their generalizability to
the general population is limited. Randomized and
independent sampling, akin to methods employed in
community-based studies, need to be considered as the
basis for future sampling efforts. Animal studies,
though community-based, generated limited data after
grouping by relevant variables, thereby limiting our
ability to delineate patterns or draw comparisons be-
tween countries over time.
Laboratory protocols Different laboratory assays were
used for antibiotic resistance testing, with automated
systems coming into use after the year 2000. Occasion-
ally, modifications to these assays were used such as
single- or double-disc diffusion, controlled agar diffusion
and gradient agar diffusion (E-test), and instances oc-
curred where two tests were employed. This was either
done in combination (to simultaneously determine anti-
biotic sensitivity and minimum inhibitory concentrations
(MICs), or when testing was done in different laborator-
ies) or separately (each test for a specific set of antibi-
otics as was the case where certain antibiotics were not
included in automated systems). Where combined test-
ing was reported, however, it was unclear how disparities
between tests were resolved in the event that this oc-
curred, or which of the test results were reported (if donein different labs). Importantly, most studies reported the
use of a reference strain or a standard, particularly E. coli
American Type Culture Collection (ATCC) 25922, with
some studies reporting use of up to six different reference
strains. Interpretation standards were equally varied al-
though most studies that reported use of a guideline after
1997 reported using the CLSI guidelines recommended by
the WHO. There were, however, reported modifications of
the common laboratory assays and it was unclear how
these were standardized to ensure agreement between
tests.
Non-standardized reporting
We noted large variability in the scope of reported data
and in some cases limited detail on the description of
study methods and results. This could have been due to
page limitations imposed by specific journals and/or the
absence of a structured reporting system for AMR re-
search. Most of the gaps in our data arose from inadequate
description of (i) study period (date and duration), (ii)
population demographics, and (iii) laboratory procedures
(isolation techniques, controls and standards). These ele-
ments, discussed below, may be critical in detecting subtle
yet significant differences between populations, procedures
and time points, differences that may otherwise not be ap-
preciated when AMR data is considered generally.
Study period Depending on the nature and duration of
a study, events (both natural and man-made) can inter-
vene during the course of a study period to skew preva-
lence data in either direction. For instance, outbreaks of
enteric diseases, commonly observed during floods or
drought can increase health facility attendance and/or
antibiotic usage thereby amplifying AMR prevalence
during such periods. As a hypothetical example, consider
cross-sectional studies conducted over period A, B and
C (Figure 3). All three occur in the same hospital but ul-
timately yield different data from each other. Providing
‘time data’ while identifying factors associated with AMR
during study periods thus becomes crucial in explaining
patterns or deviations that would otherwise be inter-
preted incorrectly.
Population demographics Factors such as age, gender,
ethnicity, environment and health status can limit the
generalizability of AMR data. Children, who often are at a
higher risk of diarrhea and other infections, are likely
greater consumers of certain types of antibiotics than
others and could contribute more to the AMR prevalence
for some antibiotics as compared to adults. In animal stud-
ies, calves have been shown to harbor more antibiotic re-
sistant bacteria than adult cattle [139]. Gender roles, on
the other hand, can have an indirect bearing on AMR by
affecting health-seeking behavior. For instance, health-
Figure 3 Hypothetical cases of diarrhea in a district hospital in 2013. Graph illustrating sources of potential differences in reported AMR
prevalence arising from monthly variations in disease incidence reported in a hospital. A, B and C represent different sampling periods.
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women whose child-rearing roles present opportunities for
seeking treatment particularly when a child is sick. Cultural
traditions and practices can also explain differences in
AMR levels and profiles. A study conducted among Maasai
in Kenya reported lower AMR prevalence than that from
other parts of the country possibly owing to their practice
of traditional medicine [23], although confounding factors
may exist in such studies. For pastoralist communities (e.g.
the Maasai in Tanzania) where antibiotic use in animals is
common (Call et al. unpub. data), common AMR profiles
in human and animal bacteria may be useful in identifying
and studying AMR zoonotic transmission pathways.
AMR prevalence can also vary by study setting. For in-
stance, Kariuki et al. [36,37] found a significantly higher
prevalence of NTS in children from informal settlements
(slums) than those from higher socio-economic classes.
These children, who were underrepresented in hospital
populations were also the majority bearers of invasive
NTS, consistent with socioeconomic barriers that limit
their presentation to health facilities in the event of failure
of self-medication. Similarly, rural populations may have,
among other differences, poorer sanitary conditions,
greater human-animal interactions, limited access to treat-
ment facilities and fewer varieties of effective antibiotics
[6,141,142], all which can impact their AMR prevalence
and profiles when compared to urban populations.
Laboratory procedures Subtle variation in laboratory
protocols can impact the interpretation of antibiotic sen-
sitivity results [143]. There are multiple steps involved inquantifying antibiotic susceptibility/resistance, and con-
sequently multiple potential sources of variation among
studies that can impact the validity of AMR data. Some
of the parameters that have been tested in this regard in-
clude the size of the inoculum (i.e. number of cells),
[143-147] growth media used, duration of incubation
and incubation temperature [7,145,146], inoculum dis-
pensing systems [146,148], delays in incubation following
disc application, depth of medium, spacing of discs, po-
tency of antibiotic discs, media composition and pH, and
subjectivity of ocular readings [7,143,145]. These factors
underscore the importance of standardized testing and
quality control that are needed to improve and maintain
the validity of AMR data; the adoption of which is still low
in the region, especially in human AMR research studies.
The individual and collective contribution of each of
these factors cannot be appreciated fully in the absence
of guidelines that ensure consistent reporting of such
variables. We propose a means for incorporating this
data when reporting AMR data (see Appendix). The op-
portunities to implement a structured AMR surveillance
system are probably limited for many low-income coun-
tries owing to competing national priorities and scarcity
of resources. Nevertheless, it is still feasible for scientists
in these regions to adopt a structured reporting mechan-
ism for AMR studies so that the data collected can be
used to make meaningful comparisons between different
studies, geographic locations and points in time. Given
widespread adoption, such guidelines should make it
possible to compile AMR trends, highlighting variation
between regions and guiding the implementation of
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otherwise be scattered amongst reports. The potential
benefits of such a venture stand to be appreciated by re-
search groups and public health policy-makers in the re-
gion and beyond.
Conclusion
There is a growing body of literature describing AMR in
sub-Saharan Africa and these studies are useful for iden-
tifying the kinds of resistance that are present in the re-
gion. Unfortunately, the focus on non-random samples
and potentially pre-selected flora combined with a very
diverse array of methodologies make it impossible to es-
timate trends in prevalence and incidence from this
body of literature. Even less is known in animal popula-
tions. We contend that at minimum, a more structured
reporting strategy is needed to aid future efforts in this
regard. Ultimately, however, a significant investment is
needed to develop a structured and rigorous region-wide
antibiotic resistance surveillance network [6]. In the in-
terim, our understanding of the AMR challenge in sub-
Saharan Africa can substantially be improved by moving
beyond descriptive studies to hypothesis-based projects that
evaluate intervention strategies. Emphasis on quantitative
assessment of risk factors rather than simply making as-
sumptions on how AMR is influenced in study populations
would be extremely valuable because inquiries such as
these will inform policy far better than accumulation of
even more descriptive and incomparable AMR studies.
Appendix: Proposed Minimum Reporting
Guidelines for Research on Antimicrobial
Resistance
See Additional file 2 for detailed rationale and defini-
tions for these guidelines. The following details should
be provided when reporting results for antimicrobial re-
sistance research:Study Structure
Design
Mention the type of study and provide a description of
its design.Dates
Indicate the months and years of the study and provide
data on any potential confounding events (e.g., natural
disasters) during the study period.Duration
State the period of time during which samples were spe-
cifically collected.Setting
Describe the sampling area specifying whether rural or
urban. Studies in mixed settings, e.g., referral hospitals,
should provide an approximate (in %) distribution of the
catchment population (urban vs rural).
Population
Give the characteristics of the chosen population includ-
ing the distribution by age (% children vs. % adults) and
sex, and indicate all categories considered (e.g., cases vs.
controls, HIV+/−, in- vs out-patient) that could influ-
ence AMR testing data.
Sampling
a. Provide the criteria used for enrollment in the
study.
b. Indicate the types of specimen collected and how
these were collected.
c. Give the overall and specific numbers of samples
collected (by category sampled).
d. Indicate how samples were processed before
storage.
Testing Procedures
Samples
a. Describe how specimens were handled, transported
and stored after collection.
b. State duration of sample storage before testing.
c. Provide the number of samples tested and indicate
reasons for exclusion, if any.
Reagents
a. Indicate brands of commercial media, controls or
antibiotic testing kits used.
b. Describe how commercial and/or in-house reagents
were prepared prior to testing.
c. Indicate the validation methods used stating cut-off
values applied.
Isolation
a. Describe the method used to obtain isolates
indicating:
i. Incubation period and temperature.
ii. Distinguish between technical and independent
replicates
iii.Methods used to identify/speciate isolates.
b. State the overall number of isolates obtained per
independent biological sample and provide an
explicit description of how these were treated in the
analyses.
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i. By source (e.g. blood, stool, pus).
ii. By category including sex and age. Note that age
is particularly important because the prevalence
of AMR bacteria can vary by age (greater in
younger hosts).
Susceptibility/resistance testing
a. Indicate the total number of isolates tested.
i. Indicate the antibiotics tested providing antibiotic
name and acronym, concentrations used, and
interpretation cut-off values that were used.
b. Describe the method(s) used to test sensitivity/
resistance indicating:
i. Type of assay used (disc diffusion, MIC,
breakpoint).
ii. Size of inoculum (McFarland’s units).
iii.Number of independent and technical replicates
included.
iv. Reference strain used as a positive control
standard.
v. Incubation temperature and period.
vi. Describe how the results were quantified:1. Zone size (mm) with X independent discs
2. MIC read by ocular estimate or using plate
reader?
3. Breakpoint [yes/no]; were small colonies
scored as present?
vii.Describe how discordant results were resolved
when more than one method was employed.
c. Specify the testing standard used (e.g. CLSI, DIN,
DANMAP)
d. Indicate quality testing procedures were used (e.g.
confirmatory testing by independent lab) and
concordance level
Results
i. Calculate the frequency of resistance to an
antibiotic as the total number of resistant isolates
divided by the total number of isolates tested with a
given antibiotic.
ii. Tabulate resistances for ALL antibiotics tested
indicating the absolute numbers or resistant
isolates, and the percent (%) of resistant isolates.
iii. Stratify results by:
a. Pathogenic species, then by
b. Source of isolate, then by
c. Age groups and gender, then by
d. Other categories used
iv. Compare categories using appropriate statistics
(contingency tests, ANOVA, etc.) with an explicit
description of how replicates were defined andhow technical vs. independent replicates were
processed (this is important to avoid issues of
pseudo-replication).Additional files
Additional file 1: Distribution of studies reporting antibiotic
susceptibility for specific pathogens.
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